Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential.
Longman
S D
SD
SmithKline Beecham Pharmaceuticals, Medicinal Research Centre, Harlow, Essex, United Kingdom.
Hamilton
T C
TC
D000818:Animals; D000959:Antihypertensive Agents / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use; D001578:Benzopyrans / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use; D002319:Cardiovascular System / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects; D002986:Clinical Trials as Topic; D019806:Cromakalim; D004195:Disease Models, Animal; D006146:Guanidines / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D009132:Muscles / Q000187:drug effects; D009474:Neurons / Q000187:drug effects; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D020108:Nicorandil; D010179:Pancreas / Q000187:drug effects; D020110:Pinacidil; D015221:Potassium Channels / Q000187:drug effects*; D011758:Pyrroles / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use
D000959:Antihypertensive Agents; D001578:Benzopyrans; D006146:Guanidines; D015221:Potassium Channels; D011758:Pyrroles; D014665:Vasodilator Agents; D019806:Cromakalim; D009536:Niacinamide; D020108:Nicorandil; D020110:Pinacidil